Lawyers squared off before the New Jersey Supreme Court on Monday for more than four hours in the mass tort alleging that the pharmaceutical giant Hoffmann-La Roche’s anti-acne drug Accutane led to users’ development of Crohn’s disease.

Last year the court agreed to determine whether a trial judge erred in barring plaintiffs’ expert testimony, and whether the plaintiffs can overcome the presumption of adequacy afforded by the Product Liability Act for a drug approved by the federal Food and Drug Administration.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]